Clinical trial · Interventional
Stage I Multiple Myeloma Treatment
NCT00733538CI-TRIAL-00075993IFM-01-04completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* Assessment of survival without progression of stage I MM in two groups: arm A: simple survey and arm B: administration of Zoledronate. * Describe different progression's type noticed and define the prognosis factors of a fast evolution.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| zometa | Drug | Zoledronic Acid | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- 1
- description
- patients receiving zometa treatment
- interventionNames
- Drug: zometa
- type
- NO_INTERVENTION
- label
- 2
- description
- No treatment, just follow-up
Primary outcomes (1)
- measure
- Survival without progress
- timeFrame
- every month during 6 years
Secondary outcomes (2)
- measure
- predictive factors of a fast evolution of multiple myeloma
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * stage I multiple myeloma without bones injuries Exclusion Criteria: * abnormal kidney function * VIH infection * Hepatic incapacity * pregnancy * Associate pathology
References
Publications (0)
Data not yet available
No reference posted for this study.